17D yellow fever vaccine + immunoglobulin

The combination of the 17D yellow fever vaccine and immunoglobulin involves co-administration of a live attenuated yellow fever virus vaccine (most commonly the 17D-204 strain as in YF-VAX) with human immune globulin containing neutralizing antibodies. The 17D yellow fever vaccine is prepared by culturing the virus in avian leukosis virus-free chicken embryos and is administered subcutaneously to induce protective immunity against yellow fever within about ten days. Immunoglobulins such as GamaSTAN S/D are derived from pooled human plasma and provide passive immunity through preformed antibodies. This combination has been studied to assess whether co-administration can reduce post-vaccination viremia or mitigate adverse events without compromising immunogenicity[1][2][5]. The primary indication for this approach is prophylaxis against yellow fever infection; however, it may be considered in special populations or research settings where modulation of immune response or risk mitigation is desired.

Brand names

GamaSTAN S/D

Other names

yellow fever vaccine (live attenuated)immune globulinISG (immune serum globulin)human immunoglobulin